IN2013MU03118A - - Google Patents

Download PDF

Info

Publication number
IN2013MU03118A
IN2013MU03118A IN3118MU2013A IN2013MU03118A IN 2013MU03118 A IN2013MU03118 A IN 2013MU03118A IN 3118MU2013 A IN3118MU2013 A IN 3118MU2013A IN 2013MU03118 A IN2013MU03118 A IN 2013MU03118A
Authority
IN
India
Prior art keywords
capecitabine
cyclophosphamide
processes
preparation
pharmaceutical compositions
Prior art date
Application number
Inventor
Patel Priyank
Patel Mayur
Patel Mahendra
Singh Balvir
Sehgal Ashish
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Priority to MX2016004094A priority Critical patent/MX2016004094A/en
Priority to EP14850037.4A priority patent/EP3052130B1/en
Priority to BR112016007031A priority patent/BR112016007031A8/en
Priority to IN3118MU2013 priority patent/IN2013MU03118A/en
Priority to ES14850037T priority patent/ES2753435T3/en
Priority to PCT/IN2014/000625 priority patent/WO2015044961A2/en
Priority to AU2014326142A priority patent/AU2014326142B2/en
Priority to US15/025,819 priority patent/US20160243034A1/en
Priority to CA2925960A priority patent/CA2925960A1/en
Publication of IN2013MU03118A publication Critical patent/IN2013MU03118A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

This present invention relates to pharmaceutical compositions comprising fixed dose combinations of capecitabine and cyclophosphamide, processes for the preparation thereof, and their use to treat cancer diseases.
IN3118MU2013 2013-09-30 2014-09-29 IN2013MU03118A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2016004094A MX2016004094A (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide.
EP14850037.4A EP3052130B1 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide
BR112016007031A BR112016007031A8 (en) 2013-09-30 2014-09-29 solid oral pharmaceutical composition, process for preparing the solid oral pharmaceutical composition, and use of a solid oral pharmaceutical composition
IN3118MU2013 IN2013MU03118A (en) 2013-09-30 2014-09-29
ES14850037T ES2753435T3 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising Capecitabine and Cyclophosphamide
PCT/IN2014/000625 WO2015044961A2 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide
AU2014326142A AU2014326142B2 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide
US15/025,819 US20160243034A1 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide
CA2925960A CA2925960A1 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3118MU2013 IN2013MU03118A (en) 2013-09-30 2014-09-29

Publications (1)

Publication Number Publication Date
IN2013MU03118A true IN2013MU03118A (en) 2015-08-14

Family

ID=52744637

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3118MU2013 IN2013MU03118A (en) 2013-09-30 2014-09-29

Country Status (9)

Country Link
US (1) US20160243034A1 (en)
EP (1) EP3052130B1 (en)
AU (1) AU2014326142B2 (en)
BR (1) BR112016007031A8 (en)
CA (1) CA2925960A1 (en)
ES (1) ES2753435T3 (en)
IN (1) IN2013MU03118A (en)
MX (1) MX2016004094A (en)
WO (1) WO2015044961A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR100820A1 (en) * 2014-06-12 2016-11-02 Sanofi-Synthelabo (India) Ltd FORMULATIONS OF COMPRESSED BI-LAYER OF CYCLOFOSPHAMIDE AND CAPECITABINE AND HIGHLY FRACTIONED METRONOMIC ADMINISTRATION OF THE SAME
US10016447B2 (en) 2014-09-26 2018-07-10 Intas Pharmaceuticals Ltd. Pharmaceutical composition having improved content uniformity
WO2017191553A1 (en) * 2016-05-03 2017-11-09 Intas Pharmaceuticals Ltd. Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US20090311249A1 (en) * 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
CA2762388A1 (en) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Oral compositions of celecoxib
WO2013028186A1 (en) * 2011-08-24 2013-02-28 Oxford Oncology Inc. Low-dose combination chemotherapy
CN103251569B (en) * 2013-05-30 2015-10-28 成都苑东药业有限公司 Capecitabine tablet composition and preparation method thereof

Also Published As

Publication number Publication date
WO2015044961A3 (en) 2015-06-04
WO2015044961A2 (en) 2015-04-02
MX2016004094A (en) 2016-10-28
BR112016007031A8 (en) 2020-02-27
AU2014326142A1 (en) 2016-04-21
CA2925960A1 (en) 2015-04-02
EP3052130B1 (en) 2019-08-07
AU2014326142B2 (en) 2019-07-25
EP3052130A4 (en) 2017-05-31
BR112016007031A2 (en) 2017-08-01
US20160243034A1 (en) 2016-08-25
EP3052130A2 (en) 2016-08-10
ES2753435T3 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
TW201613901A (en) New compounds
MX2021006531A (en) Rna containing composition for treatment of tumor diseases.
MX2023008693A (en) Modulatory polynucleotides.
GB201209613D0 (en) New compounds
TN2015000278A1 (en) Autotaxin inhibitors
MX2016002544A (en) Compounds useful as immunomodulators.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
GB201118656D0 (en) New compounds
MX366899B (en) New compounds.
MX349004B (en) New compounds.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2019013808A (en) Compounds for treatment of cancer.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
PH12014502032A1 (en) Treatment of brain cancer
MX2018003563A (en) New compounds.
TR201910866T4 (en) Combined preparations for cancer treatment.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2017009608A (en) Anti-cancer compounds.
IN2013MU03118A (en)
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
MX2018004774A (en) Substituted morpholine derivatives having activity against pain.
MX2018004776A (en) Oxa-azaspiro compounds having activity against pain.
MX2015012393A (en) Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases.